Balveen Kaur

Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.

Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.

Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.

Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.

Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population.

Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.

Genetic and hypoxic regulation of angiogenesis in gliomas.

Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Gene therapeutics: the future of brain tumor therapy?

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.

Personalizing oncolytic virotherapy?

Oncolytic viruses driven by tumor-specific promoters.

Oncolytic viruses: extreme treatment for an extreme disease.

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Advances in oncolytic virus therapy for glioma.

Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Pharmacologic and chemical adjuvants in tumor virotherapy.

Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.

"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.

Directing systemic oncolytic viral delivery to tumors via carrier cells.

Impact of tumor microenvironment on oncolytic viral therapy.

Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.

Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments.

Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.

The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNγ generation.

MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Extracellular vesicles and their convergence with viral pathways.

Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.

Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?

Gene expression profiling of the anti-glioma effect of Cilengitide.

Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations.

Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.

STAT3 activation promotes oncolytic HSV1 replication in glioma cells.

Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.

DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.